American Epilepsy Society Annual Meeting (AES)

The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.

Although the percentage of total seizures arising from REM was low, it is notable that 2 out of 26 patients (7.7%) had REM-onset seizures.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team succeeded at titrating cenobamate early in the study.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to actively look for new medications for patients to try.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team studied the interactions of ASMs and cenobamate.

The director of the Mid-Atlantic Epilepsy and Sleep Center also noted how serious adverse effects from treatment can be detrimental to patients’ lives.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.

The director of the Mid-Atlantic Epilepsy and Sleep Center also urged physicians to not give up on the search for effective AEDs for their patients.

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed how the treatment landscape for patients with Lennox-Gastaut syndrome could alter if fenfluramine is approved.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients with intractable epilepsy found cenobamate effective.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health provided his insight on the reasons for the limited number of FDA-approved seizure forecasting devices.

Efficacy was observed in patients with DEEs such as West Syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Kelly Knupp, MD, pediatric neurologist and epilepsy specialist, Children’s Hospital Colorado, detailed the findings of fenfluramine in patients with Lennox-Gastaut syndrome and how it may shake up the treatment landscape.

Neurology News Network for the week ending December 12, 2020.

Seizure reduction was observed to be sustained for up to 192 weeks in the Expanded Access Program data.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health spoke about his study presented at AES 2020 and how the next steps following the positive results.

The US Early Access Program for fenfluramine allowed access to the treatment for patients who were ineligible for clinical trials.

Patients receiving perampanel in combination with an enzyme-inducing anti-seizure medication may require a higher perampanel dose to achieve similar efficacy with only non-EIASMs.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.

Microburst stimulation was also found to be more tolerable than standard stimulation in patients with drug-resistant epilepsy.